VA Launches ProGRESS Study to Enhance Prostate Cancer Screening with Genetic Testing

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS), led by the Department of Veterans Affairs (VA), is pioneering research into the use of genetic testing to enhance prostate cancer screening. By analyzing genetic information from saliva samples, the study seeks to assess an individual's risk of developing prostate cancer, thereby tailoring screening recommendations to those at higher risk while minimizing unnecessary screenings for those at lower risk.

Why ProGRESS Matters to the VA

Prostate cancer screening, primarily through the PSA test, has been shown to slightly reduce mortality rates but also carries the risk of overdiagnosis and overtreatment. This has led to a lack of universal screening recommendations from major health organizations. The ProGRESS study aims to address this by leveraging genetic testing to provide a more precise screening approach, potentially revolutionizing how prostate cancer is detected and managed.

Study Recruitment and Participation

The ProGRESS study is recruiting Veterans aged 55-69 who have not previously undergone a prostate biopsy or MRI and have not been diagnosed with prostate cancer. Recruitment efforts include various outreach methods, aiming to enroll a diverse group of approximately 5,000 Veterans nationwide.

Consent and Biospecimen Collection

Participants can consent to the study through a web-based platform, with options for assistance and inquiries. They will provide a one-time saliva sample using a home-delivered kit, which is then analyzed for genetic risk factors related to prostate cancer.

Innovative Use of MVP Data

The study utilizes data from the Million Veteran Program (MVP) to develop the Prostate CAncer integrated Risk Evaluation (P-CARE) model. This model incorporates genetic variants, ancestry, and family history to estimate an individual's risk of developing metastatic prostate cancer.

Randomization and Intervention

Participants are randomized into two groups: one receiving personalized screening recommendations based on their genetic profile, and the other following standard screening practices. This approach aims to evaluate the effectiveness of precision screening in improving prostate cancer outcomes.

Follow-Up and Resources

All participants will engage in prostate health surveys over a period of up to 10 years, contributing valuable data to the study's findings. The ProGRESS study is a collaborative effort involving several institutions, including the Broad Institute and VA facilities, highlighting the VA's commitment to advancing prostate cancer research and care for Veterans.